Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis

[1]  J. Wargo,et al.  Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab , 2020, Clinical Cancer Research.

[2]  G. Hortobagyi,et al.  Current Landscape of Immunotherapy in Breast Cancer: A Review. , 2019, JAMA oncology.

[3]  A. Rosenberg,et al.  Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[4]  H. Tawbi,et al.  Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. , 2019, Journal of Clinical Oncology.

[5]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[6]  M. Levitt,et al.  Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study , 2019, Journal of clinical medicine research.

[7]  R. Herbst,et al.  Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes , 2019, Clinical Cancer Research.

[8]  A. Benito,et al.  Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review , 2019, Respiratory medicine case reports.

[9]  Jason M. Johnson,et al.  Characteristics of mismatch repair deficiency in sarcomas , 2019, Modern Pathology.

[10]  Z. Duan,et al.  Advances in immune checkpoint inhibitors for bone sarcoma therapy , 2019, Journal of bone oncology.

[11]  R. Munker,et al.  Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review , 2018, European journal of haematology.

[12]  K. Hunt,et al.  Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma , 2018, BMC Cancer.

[13]  G. Rossi,et al.  Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis , 2018, Case Reports in Oncology.

[14]  S. Baxi,et al.  Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis , 2018, British Medical Journal.

[15]  C. Antonescu,et al.  Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. , 2018, The Lancet. Oncology.

[16]  J. Taube,et al.  PD-L1 Expression in Inflammatory Myofibroblastic Tumors , 2018, Modern Pathology.

[17]  Publisher's Note , 2018, Anaesthesia.

[18]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[19]  D. Jamieson,et al.  Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial , 2017 .

[20]  H. Shim,et al.  PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors , 2017, Oncotarget.

[21]  Robin L. Jones,et al.  First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient , 2017, Journal of immunotherapy.

[22]  F. Hodi,et al.  Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study , 2017, Cancer.

[23]  Robin L. Jones,et al.  T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas , 2017, Cancer.

[24]  J. Blay,et al.  Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study , 2017, BMC Medicine.

[25]  S. Fröhling,et al.  PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma , 2017, Oncoimmunology.

[26]  Robin L. Jones,et al.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis , 2017, Acta oncologica.

[27]  J. Blay,et al.  Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. , 2016, The Lancet. Oncology.

[28]  J. Kopecký,et al.  Microsatellite instability as a predictive factor for immunotherapy in malignant melanoma. , 2016, Medical hypotheses.

[29]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[30]  H. Lyerly,et al.  Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer , 2016, Current Treatment Options in Oncology.

[31]  A. Italiano,et al.  Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype , 2016, Modern Pathology.

[32]  J. Blay,et al.  Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.

[33]  J. Blay,et al.  Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. , 2014, European journal of cancer.

[34]  C. Fournier,et al.  Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) , 2013, Investigational New Drugs.

[35]  D. Rimm,et al.  Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1) , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  A. Santoro,et al.  Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Schiffman,et al.  Microsatellite Instability in Sarcoma: Fact or Fiction? , 2012, ISRN oncology.

[38]  A. Lazar,et al.  Lymphocyte composition and distribution in inflammatory, well-differentiated retroperitoneal liposarcoma: clues to a potential adaptive immune response and therapeutic implications. , 2012, The American journal of surgical pathology.

[39]  J. Maurel,et al.  Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Antonescu,et al.  Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Blay,et al.  Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Blay,et al.  Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  J. Desai,et al.  Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas , 2007, Cancer.

[46]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[47]  R. Maki,et al.  A Retrospective Analysis of Vinorelbine Chemotherapy for Patients With Previously Treated Soft-Tissue Sarcomas , 2006, Sarcoma.

[48]  J. Blay,et al.  Docetaxel and gemcitabine combination in 133 advanced soft‐tissue sarcomas: A retrospective analysis , 2006, International journal of cancer.

[49]  A. Troxel,et al.  A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma , 2003, Cancer.

[50]  V. Bramwell,et al.  Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. , 2003, The Cochrane database of systematic reviews.

[51]  O. S. Nielsen,et al.  Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. , 2002, European journal of cancer.

[52]  J. Crowley,et al.  An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  G. Weiss,et al.  Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. , 1991, Journal of the National Cancer Institute.

[54]  J. Verweij,et al.  High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma Group. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  A. Elias,et al.  Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  J. Mulder,et al.  Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. , 1987, European journal of cancer & clinical oncology.

[57]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[58]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[59]  J. Blay,et al.  Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial , 2018, JAMA oncology.

[60]  A. Cleton-Jansen,et al.  Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers , 2018, Laboratory Investigation.

[61]  M. Toulmonde,et al.  PD-1 inhibition in sarcoma still needs investigation. , 2018, The Lancet. Oncology.

[62]  M. Suarez‐Almazor,et al.  Adverse Events in Cancer Immunotherapy. , 2017, Advances in experimental medicine and biology.

[63]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[65]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.